PMID- 28380027
OWN - NLM
STAT- MEDLINE
DCOM- 20170905
LR  - 20190208
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role
      for future cancer using non-malignant prostate biopsies.
PG  - e0175070
LID - 10.1371/journal.pone.0175070 [doi]
AB  - BACKGROUND: Prostate Cancer 3 (PCA3) is a long non-coding RNA (ncRNA) upregulated
      in prostate cancer (PCa). We recently identified a short ncRNA expressed from
      intron 1 of PCA3. Here we test the ability of this ncRNA to predict the presence 
      of cancer in men with a biopsy without PCa. METHODS: We selected men whose
      initial biopsy did not identify PCa and selected matched cohorts whose subsequent
      biopsies revealed PCa or benign tissue. We extracted RNA from the initial biopsy 
      and measured PCA3-shRNA2, PCA3 and PSA (qRT-PCR). RESULTS: We identified 116 men 
      with and 94 men without an eventual diagnosis of PCa in 2-5 biopsies (mean 26
      months), collected from 2002-2008. The cohorts were similar for age, PSA and
      surveillance period. We detected PSA and PCA3-shRNA2 RNA in all samples, and PCA3
      RNA in 90% of biopsies. The expression of PCA3 and PCA3-shRNA2 were correlated
      (Pearson's r = 0.37, p<0.01). There was upregulation of PCA3 (2.1-fold, t-test p 
      = 0.02) and PCA3-shRNA2 (1.5-fold) in men with PCa on subsequent biopsy, although
      this was not significant for the latter RNA (p = 0.2). PCA3 was associated with
      the future detection of PCa (C-index 0.61, p = 0.01). This was not the case for
      PCA3-shRNA2 (C-index 0.55, p = 0.2). CONCLUSIONS: PCA3 and PCA3-shRNA2 expression
      are detectable in historic biopsies and their expression is correlated suggesting
      co-expression. PCA3 expression was upregulated in men with PCa diagnosed at a
      future date, the same did not hold for PCA3-shRNA2. Futures studies should
      explore expression in urine and look at a time course between biopsy and PCa
      detection.
FAU - Pang, Karl H
AU  - Pang KH
AD  - Academic Urology Unit and Academic Unit of Molecular Oncology, Department of
      Oncology and Human Metabolism, University of Sheffield, Sheffield, United
      Kingdom.
FAU - Rosario, Derek J
AU  - Rosario DJ
AD  - Academic Urology Unit and Academic Unit of Molecular Oncology, Department of
      Oncology and Human Metabolism, University of Sheffield, Sheffield, United
      Kingdom.
FAU - Morgan, Susan L
AU  - Morgan SL
AD  - Department of Histopathology, Royal Hallamshire Hospital, Sheffield, United
      Kingdom.
FAU - Catto, James W F
AU  - Catto JW
AD  - Academic Urology Unit and Academic Unit of Molecular Oncology, Department of
      Oncology and Human Metabolism, University of Sheffield, Sheffield, United
      Kingdom.
LA  - eng
PT  - Journal Article
DEP - 20170405
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (RNA, Small Untranslated)
RN  - 0 (prostate cancer antigen 3, human)
SB  - IM
MH  - Antigens, Neoplasm/*genetics/physiology
MH  - Biopsy
MH  - Case-Control Studies
MH  - Genetic Predisposition to Disease/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostate/*pathology
MH  - Prostatic Neoplasms/*genetics
MH  - RNA, Small Untranslated/*genetics/physiology
MH  - Transcriptome
PMC - PMC5381913
EDAT- 2017/04/06 06:00
MHDA- 2017/09/07 06:00
CRDT- 2017/04/06 06:00
PHST- 2016/10/09 00:00 [received]
PHST- 2017/03/20 00:00 [accepted]
PHST- 2017/04/06 06:00 [entrez]
PHST- 2017/04/06 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
AID - 10.1371/journal.pone.0175070 [doi]
AID - PONE-D-16-40265 [pii]
PST - epublish
SO  - PLoS One. 2017 Apr 5;12(4):e0175070. doi: 10.1371/journal.pone.0175070.
      eCollection 2017.